Neuren Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

Neuren Pharmaceuticals 의 총 주주 지분은 A$219.2M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$228.2M 및 A$9.0M 입니다. Neuren Pharmaceuticals 의 EBIT는 A$155.2M 이며 이자보상배율은 -14.3 입니다. A$213.2M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	-14.3x
현금	AU$213.17m
주식	AU$219.15m
총 부채	AU$9.00m
총 자산	AU$228.15m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: NURP.F 의 단기 자산 ( A$228.0M )이 단기 부채( A$9.0M ).

장기 부채: NURP.F 의 단기 자산( A$228.0M )이 장기 부채( A$29.0K ).

부채 대 자본 내역 및 분석

부채 수준: NURP.F 부채가 없습니다.

부채 감소: NURP.F 지난 5년간 부채가 없습니다.

부채 범위: NURP.F 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: NURP.F 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Neuren Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 Trials

Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.

Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in funding

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in funding

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기